3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Nasopharyngeal Carcinoma
14
Triple Negative Breast Neoplasms
12
Carcinoma, Non-Small-Cell Lung
10
Esophageal Squamous Cell Carcinoma
9
Breast Neoplasms
8
Colorectal Neoplasms
7
Carcinoma, Renal Cell
7
Small Cell Lung Carcinoma
6
Neoplasms
6
Advanced Solid Tumor
6
Uterine Cervical Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
5
Head and Neck Neoplasms
5
Urinary Bladder Neoplasms
4
Recurrence
4
Carcinoma, Hepatocellular
4
Stomach Neoplasms
3
Solid Tumor
3
Neoplasm Metastasis
3
Liver Neoplasms
3
Carcinoma, Transitional Cell
3
Turcot syndrome
2
Sarcoma
2
Oropharyngeal Neoplasms
2
Nasopharyngeal Neoplasms
2
NSCLC
2
Muscle Invasive Bladder Cancer (MIBC)
2
Carcinoma, Squamous Cell
2
Biliary Tract Neoplasms
2
Advanced Solid Tumors
2
Interventions
lutetium Lu 177 dotatate
20
Magnetic Resonance Spectroscopy
10
pembrolizumab
9
Specimen Handling
7
Everolimus
7
cabozantinib
6
Nivolumab
6
lenvatinib
5
177Lu-octreotide, DOTA(0)-Tyr(3)-
5
surufatinib
4
amino-acid, glucose, and electrolyte solution
4
Capecitabine
4
olaparib
3
lanreotide
3
atezolizumab
3
Temozolomide
3
Octreotide
3
Lutetium-177
3
Ipilimumab
3
Injections
3
Fluorodeoxyglucose F18
3
Cyclophosphamide
3
gallium Ga 68 dotatate
2
fludarabine phosphate
2
fludarabine
2
avelumab
2
X-Rays
2
Radiotherapy
2
Phantoms, Imaging
2
PM 01183
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
toripalimab
×
1 year
×
Clear all
No trials found.